

Cite this: *Chem. Sci.*, 2024, 15, 1846

All publication charges for this article have been paid for by the Royal Society of Chemistry

# *In silico* MS/MS prediction for peptidoglycan profiling uncovers novel anti-inflammatory peptidoglycan fragments of the gut microbiota†

Jeric Mun Chung Kwan,<sup>ab</sup> Yaquan Liang,<sup>a</sup> Evan Wei Long Ng,<sup>a</sup> Ekaterina Sviriaeva,<sup>b</sup> Chenyu Li,<sup>a</sup> Yilin Zhao,<sup>a</sup> Xiao-Lin Zhang,<sup>a</sup> Xue-Wei Liu,<sup>a</sup> Sunny H. Wong<sup>b</sup> and Yuan Qiao<sup>ab\*</sup>

Peptidoglycan is an essential exoskeletal polymer across all bacteria. Gut microbiota-derived peptidoglycan fragments (PGNs) are increasingly recognized as key effector molecules that impact host biology. However, the current peptidoglycan analysis workflow relies on laborious manual identification from tandem mass spectrometry (MS/MS) data, impeding the discovery of novel bioactive PGNs in the gut microbiota. In this work, we built a computational tool PGN\_MS2 that reliably simulates MS/MS spectra of PGNs and integrated it into the user-defined MS library of *in silico* PGN search space, facilitating automated PGN identification. Empowered by PGN\_MS2, we comprehensively profiled gut bacterial peptidoglycan composition. Strikingly, the probiotic *Bifidobacterium* spp. manifests an abundant amount of the 1,6-anhydro-MurNAc moiety that is distinct from Gram-positive bacteria. In addition to biochemical characterization of three putative lytic transglycosylases (LTs) that are responsible for anhydro-PGN production in *Bifidobacterium*, we established that these 1,6-anhydro-PGNs exhibit potent anti-inflammatory activity *in vitro*, offering novel insights into *Bifidobacterium*-derived PGNs as molecular signals in gut microbiota-host crosstalk.

Received 31st October 2023  
Accepted 19th December 2023

DOI: 10.1039/d3sc05819k

rsc.li/chemical-science

## Introduction

All bacteria possess a peptidoglycan layer. As an essential exoskeletal polymer that surrounds the bacterial cytoplasmic membrane, peptidoglycan protects bacterial cells against internal turgor pressure and also serves as a scaffold for other cell surface proteins and polymers.<sup>1</sup> Apart from a structural role, bacterial peptidoglycan also participates in diverse intra- and inter-kingdom signalling.<sup>2,3</sup> Soluble peptidoglycan fragments, also known as PGNs or muropeptides, are continuously generated by bacteria during growth and released into the milieu, exerting a broad-range impact on different organisms.<sup>4</sup> In the context of the human gut microbiota, trillions of resident bacteria produce a multitude of PGNs in the gut niche,<sup>5</sup> which can disseminate into host systemic circulation under steady-state conditions,<sup>6</sup> influencing host biology including autoimmunity, brain development, appetite, and body temperature, as well as efficacies of cancer immunotherapy.<sup>7–10</sup> Remarkably,

subtle structural changes in PGNs can significantly alter their biological activities in hosts.<sup>11</sup> Thus, profiling peptidoglycan compositions and characteristics in gut bacteria is of paramount importance to facilitate studies of gut microbiota-derived PGNs in hosts.

While the chemical makeup of peptidoglycan polymers is largely conserved, the exact compositions and structural modifications of peptidoglycan are highly variable across bacteria and under different environmental conditions (Fig. 1).<sup>1,12,13</sup> In general, the ‘glycan’ component of peptidoglycan consists of alternating units of *N*-acetylglucosamine (GlcNAc, or herein NAG) and *N*-acetylmuramic acid (MurNAc, or herein NAM) linked *via*  $\beta$ -1,4-glycosidic bonds; the ‘peptido’ portion refers to the short stem pentapeptide connected onto the lactoyl group of each NAM, which has the common sequence L-Ala<sub>1</sub>- $\gamma$ -D-Glu/isoGln<sub>2</sub>-AA<sub>3</sub>-D-Ala<sub>4</sub>-D-Ala<sub>5</sub>, with AA<sub>3</sub> being either L-Lys attached to a lateral bridge peptide (that is specific to each bacterial species) or a non-proteogenic diamino acid such as meso-diaminopimelic acid (mDAP) (Fig. 1A). These stem peptides on adjacent glycan strands can form 3–4 or 3–3 crosslinks through iso-peptide bonds, thereby strengthening the peptidoglycan layer (Fig. 1C). Furthermore, a great deal of structural diversity in peptidoglycan comes from the cell wall remodeling process, where bacterial enzymes catalyze specific reactions at distinct positions in peptidoglycan to generate new structural moieties, such as modifications of the glycan

<sup>a</sup>School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, 637371, Singapore. E-mail: yuan.qiao@ntu.edu.sg

<sup>b</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, 308232, Singapore

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3sc05819k>





Fig. 1 Schematic representations of bacterial peptidoglycan compositions (A–C) and our *in silico* peptidoglycan fragment (PGN) library analysis pipeline (D). (A) Peptidoglycan is composed of repeating muropeptide units, *i.e.*, *N*-acetylglucosamine (NAG)-*N*-acetylmuramic acid (NAM) disaccharides with a stem peptide. Various modifications can be present on the disaccharide backbone (right). Glu: glutamate and isoGln: iso-glutamine; mDAP: meso-diaminopimelic acid. (B) Remodelling of peptidoglycan may include trimming of stem peptides and/or incorporation of non-canonical D-amino acids (striped box). (C) Stem peptides can be crosslinked *via* direct crosslinks (left, for mDAP-type PGN) or indirect crosslinks, attached through a species-specific bridge peptide (right, for L-Lys type PGN). (D) Manual analysis of MS/MS spectra for structural determination is a bottleneck in bacterial PGN analysis. PGN\_MS2 (bottom box) creates a PGN database that includes *in silico* predicted MS/MS spectra. The resulting spectral library (.msp) is open-access and compatible with mass spectra analysis software for automated deconvolution and analysis of PGNs using *m/z*, isotopic pattern, and spectral similarity from the LC-MS/MS raw data.

backbone, trimming of pentapeptides to shorter stems, and incorporation of non-canonical D-amino acids (NCDAA) into the stem peptide (Fig. 1A and B).<sup>14</sup> While most insights on peptidoglycan structural diversity were gained from analyses of model bacterial organisms, our knowledge of the scope and variety of peptidoglycan in the gut microbiota is still in its infancy. Recognizing the biological significance of peptidoglycan modifications, we seek to develop a robust and

automated workflow to characterize peptidoglycan compositions and structural features in any bacteria of interest, especially those in the gut microbiota.

There are significant gaps in the current workflow of bacterial peptidoglycan analysis, with the widely adopted experimental procedure developed >30 years ago.<sup>15</sup> Briefly, the peptidoglycan polymer (*i.e.*, sacculi) isolated from bacteria is digested with a muramidase (*e.g.*, lysozyme) that hydrolyzes the



NAM- $\beta$ -1,4-NAG linkages along the peptidoglycan backbone, generating soluble PGNs that are disaccharide-containing muropeptides in nature.<sup>16</sup> The collection of these soluble PGNs is then subjected to high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis for structural characterization and profiling (Fig. 1D, top row). Improvements in HPLC-MS/MS instrumentation such as higher resolution and faster scanning rate have improved the quality of acquired data; however, analyzing raw MS data to elucidate PGN structures remains a painstaking manual task, where one needs to come up with the potential structures of PGNs (*i.e.*, search space, which can be as large as >6000 structures on ChemDraw)<sup>17,18</sup> and look for matches of the expected  $m/z$  values in the acquired LC-MS dataset. Such manual annotations of MS data are considerably time-consuming, laborious, and inconsistent, remaining as an undesirable bottleneck for robust and comprehensive peptidoglycan analysis with higher throughput.<sup>19,20</sup> This may deter the discovery of novel structural features of peptidoglycan, especially in the gut microbiota, where the scope of peptidoglycan diversity has not been much explored.

Towards these challenges, we present a novel and customizable PGN database integrated with *in silico* MS/MS spectra to enable automated MS/MS deconvolution for PGN identification (Fig. 1D, bottom row). The spectral library (.msp format) encompasses the *in silico* predicted MS/MS fragmentation for each PGN in the dataset, which is compatible with open-access and vendor software for automated matching and scoring of the experimental MS/MS peaks, thus streamlining PGN analysis with unmatched confidence and throughput. Applying this automated PGN analysis pipeline, we profiled the peptidoglycan compositions of five different gut bacteria. Intriguingly, an unusually high abundance of anhydro-PGNs (*i.e.*, PGNs containing a 1,6-anhydro-muramyl moiety, anNAM) (Fig. 1A, far right) was found in *Bifidobacterium*, the common probiotic bacteria that confer anti-inflammatory effects in hosts.<sup>21,22</sup> We further demonstrated that MltG and RfpB homologs in *Bifidobacterium* possess robust lytic transglycosylase (LT) activity towards distinct peptidoglycan substrates to generate anhydro-PGN moieties. Importantly, we established that these anhydro-PGNs of *Bifidobacterium* exhibit novel anti-inflammatory effects *in vitro*, which opens up exciting opportunities for postbiotic development.

## Results

### Generation of a customizable PGN MS1 database

To streamline the PGN searching process, we envisioned a method to automatically generate a PGN MS1 database with user-defined parameters. The basic muropeptide scaffold of PGNs (upon muramidase digestion in the sample preparation) features a (NAG)(NAM) disaccharide with a stem peptide, where distinct structural modifications are possible at each position.<sup>1</sup> To build the PGN database, the user, through a graphical user interface, conveniently selects the possible range of modifications on the (NAG)(NAM) backbone, including *O*-acetylation, de-*N*-acetylation, or anNAM termini, followed by selecting the

possible amino acid identities at each stem peptide position. Next, additional structural modifications can be included, such as Braun's lipoprotein attachment, substitution of the terminal amino acid with lactate, endopeptidase-cleaved products, and reduction of muramyl termini. Lastly, the user can select the amount and types of PGN polymerization, either through peptide crosslinks or glycosidic bonds. All parameters can be adjusted. Next, PGN molecules are constructed *in silico* with RDKit,<sup>23</sup> and the database is saved as an Excel worksheet (.xlsx). Each PGN is assigned a unique descriptive name (Fig. S1†). With the graphical user interface, no coding experience from the user is required to build the PGN database (Fig. S2 and S1†).

Apart from its descriptive name, the PGN database (.xlsx) also includes chemical descriptors for individual PGNs, *e.g.*, chemical formula, adducts  $m/z$ , clogP, InChIKey, SMILES, and PGN-specific descriptors, *e.g.*, the degree of acetylation, degree of amidation, and stem peptide length, thereby facilitating subsequent PGN categorization and comparative analysis (Fig. 2, right). Accompanying the PGN database, an image output that summarizes user-defined parameters is automatically generated for convenient referencing (Fig. 2, left). For a typical database of 3000–10 000 PGNs, it takes ~1 min per 1000 PGN to generate when run on a computer with a 2.60 GHz processor and 16 GB RAM. To reduce analysis time, PGN\_MS2 includes various ways to skip illogical/unreasonable PGN polymers (Table S1†).

### Development of PGN\_MS2 for *in silico* MS/MS prediction

Although PGNs can be identified by their  $m/z$  values alone (MS1 identification), additional analysis by tandem mass spectrometry (MS/MS) is necessary to resolve structural isomers of PGNs with mass coincidences. In the fields of metabolomics and proteomics, compound identification is routinely performed by matching and scoring experimental MS/MS spectra against a reference library of actual MS/MS spectra of standard compounds and/or *in silico* simulated MS/MS spectra for compounds whose experimental data are not available.<sup>24–27</sup> Given the limited availability of empirically collected MS/MS data, *in silico* MS/MS prediction can greatly improve compound identification.<sup>28</sup> However, due to the unique sugar and amino acid compositions present in PGNs, existing MS/MS simulation tools in metabolomics and proteomics are not well-suited for PGN identification.<sup>19</sup> Toward the automated PGN analysis workflow, we next sought to augment the PGN MS1 database with *in silico* predicted MS/MS spectra.

To derive *in silico* PGN MS/MS spectra, we first studied the ESI-MS/MS spectra of known PGNs. Recent studies by Tan *et al.* and Anderson *et al.* reported the experimental MS/MS spectra for selected PGNs from *E. coli*, *S. aureus*, and *P. aeruginosa*, providing a suitable starting point for our evaluation.<sup>17,29</sup> In addition, we also acquired experimental LC-HRMS/MS data for several major PGNs with known structures from *E. faecalis* and *L. plantarum*. Notably, these spectra were acquired using different MS instruments, namely, Orbitrap Exploris 120 (our study), LCQ Fleet (Tan *et al.*), and Q-TOF (Anderson *et al.*),





**Fig. 2** Example of an image output that summarizes the diversity of PGNs present in the user-defined *in silico* PGN library (left). The glucosamines (blue), muramic acids (green), and amino acids (numbered white boxes) used to construct PGNs are listed. Bridge peptide sequences are indicated to the right of the connecting amino acid with a connecting line. Its color indicates the type of connection (red: through COOH; blue:  $\text{NH}_2$ ). The user-defined canonical components are bolded. Glycan lengths (0–2 glycans), peptide lengths (0–5 amino acids), and polymerizations (0 to 2) are indicated. Peptidoglycan modifications are listed in the top-right corner. The requirement for each polymerization is shown at the bottom. For instance, G–G polymerization is only formed between PGNs with glycan length 2, peptide lengths 0–5, and with either Ala, Gly or no amino acid in positions 4/5 on both the acceptor and donor. N- and C-peptide termini are colored blue and red, respectively. The PGN library is saved as an Excel file (.xlsx) which contains their chemical and PGN-specific descriptors (right).

enabling us to derive common ESI-MS/MS fragmentation rules for most PGNs. We recognized that the PGN precursor ions frequently undergo B/Z-type glycan fragmentation (nomenclature according to Domon and Costello<sup>30</sup>) and b/y-type peptide fragmentation, with multiple b/y cleavages to yield lighter ions (Fig. 3A). Additionally, the lactoyl bond connecting the glycan and peptide in PGNs also fragments readily, with the peptide fragment ion henceforth named L (Fig. 3A). Furthermore, isomeric PGNs that contain stem peptides such as Aqm and Aem( $\text{NH}_2$ ) with differing amidation positions can be easily distinguished by their MS/MS patterns (Fig. S3†). The y2 peptide fragments (*i.e.* qm or em( $\text{NH}_2$ ),  $m/z$ : 319.1619) undergo further e1/e2 or q1/q2 fragmentations due to prominent neutral losses at the N-terminus.<sup>31</sup> For instance, em( $\text{NH}_2$ ) yields 301.1465 (e1) and 256.1280 (e2) fragments, whereas qm gives rise to signature MS/MS peaks of 302.1347 (q1) and 257.1103 (q2); with q2 fragments showing higher relative intensities (Fig. S3A and B†). These abundant MS/MS features are useful to distinguish PGNs that bear e or q in the stem peptides, as in the case of *L. plantarum* (Fig. S3†). Upon evaluating the experimental MS/MS spectra for ~30 PGNs, we found that most of the fragmentation peaks can be explained by 19 fragmentation reactions or a combination thereof (Fig. 3A).

Based on these common fragmentation reactions, we developed PGN\_MS2, an *in silico* MS/MS prediction tool for


PGNs. As shown in Fig. 3B, we encoded each fragmentation as a chemical reaction in SMARTS and simulated it with RDKit.<sup>23</sup> Each parental PGN ion (generation-0) is fragmented *via* all possible 19 reactions to form generation-1 product ions, which are further fragmented to yield generation-2 and generation-3 product ions sequentially. Fragmentation is discontinued after no new product ions are generated. For every fragmentation, the  $m/z$  value and relative intensity for each fragment are calculated. Relative intensity is estimated based on an empirically derived formula (that accounts for the number of peptide bonds or mass ratio of the precursor and product ions) together with a fragmentation-specific adjustment factor. Finally, the assembly of possible fragment ions affords the *in silico* predicted MS/MS spectra. To account for the different precursor adducts (*i.e.*,  $[\text{M} + \text{H}]^+$ ,  $[\text{M} + 2\text{H}]^{2+}$ , and  $[\text{M} + 3\text{H}]^{3+}$ ), separate MS/MS spectra are created for each adduct, whereby fragment ions with  $m/z$  greater than that of the precursor ion are removed. In sum, our PGN library integrates the predicted MS/MS spectra of all PGNs in the database as a NIST format text file (.msp, Fig. S2C†).

### Reliable PGN identification with *in silico* MS/MS prediction

To test the accuracy and reliability of MS/MS prediction by PGN\_MS2, we first compared the experimental spectra of a panel of distinct PGNs from different bacteria with their







**Fig. 3** The design and construction of *in silico* PGN fragmenter, PGN\_MS2. (A) Empirical analysis of PGN MS/MS spectra reveals the possible types of fragmentation reactions, which are encoded using PGN\_MS2. Fragmentation of the glycan backbone (B/Y/C/Z) follows Domon and Costello's nomenclature; fragmentation of the stem peptide is denoted as bn and yn, where n indicates the position of the peptide bond, with the peptide bond nearest to the glycan backbone denoted as "1"; fragmentation of the bridge peptide is indicated with a quotation mark ('). In addition, the  $\gamma$ -Glu-containing PGNs yield e1/e2 fragments due to the neutral loss of H<sub>2</sub>O and COOH + NH<sub>3</sub>, respectively; similarly,  $\gamma$ -isoGln-containing PGNs generate q1/q2 fragments by neutral loss of NH<sub>3</sub> and CONH<sub>2</sub> + NH<sub>3</sub>, respectively. Furthermore, further fragmentation of GlcNAc/MurNAc (Glc-1, Glc-2, Glc-3, and Mur-1) and neutral loss of H<sub>2</sub>O or NH<sub>3</sub> are also included as fragmentation reactions. (B) *In silico* MS/MS spectrum generation schematic. The fragmentation reactions for each PGN are encoded as SMARTS, where the *m/z* and relative intensity are calculated for each product ion. Each product ion undergoes further fragmentation (2 repeats) to create the *in silico* spectrum. (C) Comparison of experimental MS/MS spectra (top, red) vs. *in silico* predicted spectra (bottom, blue) for canonical PGN in *E. coli* (left) and *S. aureus* (right). Matched peaks are coloured black, and the cosine similarity scores between the spectra are shown in the top right corner.

respective predicted spectra by calculating the cosine spectral similarity scores.<sup>32</sup> As expected, PGN\_MS2 consistently afforded high similarity scores of 0.7–0.8 for most PGNs, which significantly outperformed other spectral prediction tools such as CFM-ID and ms2pip (Fig. S4A–C, Table S2†),<sup>26,27</sup> showcasing the specialized applications of PGN\_MS2 for PGN analysis. In addition, we validated PGN\_MS2 by demonstrating its ability to predict MS/MS spectra of synthetic PGN standards (Fig. S4D†).

Next, we confirmed that the *in silico* predicted spectra by PGN\_MS2 match well with the MS/MS spectra acquired using either an Orbitrap spectrometer *via* higher-energy C-trap dissociation (HCD)-based fragmentation or a Q-TOF instrument *via* collisional dissociation (CID)-based fragmentation (Fig. S5A–D†).<sup>33</sup> In addition, to benchmark our PGN\_MS2 with the available PGN dataset, we also evaluated the experimental data of *P. aeruginosa* PGNs deposited by Anderson *et al.*, which

was collected using a Q-TOF mass spectrometer.<sup>17</sup> Consistently, using PGN\_MS2 and MS-DIAL, we readily confirmed 54 PGNs that were manually identified in the previous work (62, with MS/MS) (Fig. S5E–F†). Taken together, our observations demonstrate the robustness and reliability of PGN\_MS2 in simulating ESI-MS/MS spectra of PGNs for structural determination.

To further investigate if PGN\_MS2 could indeed aid accurate assignment of PGNs among closely related structural isomers, we challenged it to identify the canonical *E. coli* or *S. aureus* PGN, (NAG)(NAM)-Aema and (NAG)(NAM)-AqKAA[3-NH<sub>2</sub>-GGGGG] respectively, from a set of four intentionally generated mock PGNs with identical molecular formulae (Fig. S6†). Satisfactorily, we correctly assigned the two PGN structures, since they both emerged as the top hits with the highest spectral similarity scores compared to other possible isomers, albeit by a small margin (Fig. S6†). Based on our analysis, we noted that



although the top matched *in silico* PGN usually represents the accurate structure, other criteria such as the presence or absence of certain signature MS/MS fragments are particularly useful for PGN determination too. For instance, fragments containing the intact mDAP–mDAP bond (*i.e.*,  $m/z$ : 617.2777, 746.3203, and 889.3785) are observed in the MS/MS spectra of the 3–3 but not 3–4 crosslinked PGNs in *E. coli*, allowing convenient distinction between the two isomers (Fig. 4C and S7†). Therefore, it is prudent to check for these signature fragments for PGN identification. To assist with this, PGN\_MS2 also annotates the chemical structures of each fragment in the predicted MS/MS spectra as SMILES (Fig. S2D†).

### Validation of the MS/MS-integrated workflow for model bacterial PGN profiling

Upon demonstrating the reliability of PGN\_MS2 for identifying individual PGN molecules, we then sought to evaluate its potential application for profiling bacterial peptidoglycan compositions. We first constructed PGN libraries customized for different model bacteria, including *E. coli*, *S. aureus*, *E. faecium*, and *L. plantarum*. We next acquired experimental LC-HRMS/MS data of PGNs from these bacteria. NaBH<sub>4</sub> reduction was omitted to prevent potential acid hydrolysis during the addition of phosphoric acid and preserve the natural structure of PGN. Next, we utilized open-source software MS-DIAL for automated data analysis by importing the respective *in silico* MS/MS libraries as spectral references for PGN identification.<sup>34</sup> In general, our findings are consistent with previous knowledge of PGN compositions in these bacteria,<sup>16,35–43</sup> validating our MS/MS-integrated PGN MS library for automated PGN profiling. We summarized the canonical PGN monomeric makeup (Fig. 4A and S8G†) and listed the detailed PGN compositions in these bacteria (Tables S3–S8†). Below we highlight the discovery of several PGN structural features that exemplify the virtue of the *in silico* MS/MS spectral library.

Amidation of stem peptides is a unique feature in PGNs of Gram-positive bacteria (Fig. 5B).<sup>1</sup> For instance, the canonical monomeric PGNs in *E. faecium* and *L. plantarum* each contain two possible amidated residues in the stem peptides, q and isoAsn, q and m(NH<sub>2</sub>), respectively (Fig. 4A). Although most PGNs in both bacteria are amidated at both positions, substantial amounts of singly amidated PGNs are also observed, which require MS/MS analysis to determine the exact amidation position in the isomeric PGNs (Fig. S3†). In addition, some *L. plantarum* PGNs have D-lactate instead of D-Ala at the stem peptide's terminus,<sup>43</sup> which further complicates identification. The three structural isomers, (NAG)(NAM)-Aem(NH<sub>2</sub>)AA, (NAG)(NAM)-AqmAA, and (NAG)(NAM)-Aqm(NH<sub>2</sub>)ALac have identical  $m/z$  values that are indistinguishable solely based on MS1 analysis and require in-depth MS/MS evaluation. With our approach, the *in silico* predicted MS/MS spectra by PGN\_MS2 revealed signature fragments for each of the three PGN isomers, which significantly improved the confidence and throughput of MS/MS identification (Fig. S9†). For instance, the experimental spectra of (NAG)(NAM)-Aqm(NH<sub>2</sub>)ALac showed the best match to the *in silico* spectra for this particular isomer and contained

all key fragments, allowing us to easily assign the correct structure (Fig. S9†). Moreover, with our MS/MS-integrated analysis pipeline, we also uncovered that amidation at the second residue (q) of the stem peptide is more prominent than that at the side chain ( $\beta$ -Asp) in *E. faecium*, whereas similar amidation rates were observed for both q and m(NH<sub>2</sub>) in PGNs of *L. plantarum* (Fig. S8A†).<sup>43</sup> Recognizing that bacterial peptidoglycan amidations are associated with increased levels of crosslinking and also implicate antibiotic resistance,<sup>44–49</sup> we anticipate that our workflow for the facile analysis of such amidated PGNs will facilitate the development of novel antimicrobials targeting bacterial peptidoglycan amidations.

Peptidoglycan crosslinking *via* stem peptides confers strength and resistance to certain antibiotics and stress conditions. For instance, *E. coli* typically manifests 3–4 crosslinking but significantly increases 3–3 crosslinking under stress conditions.<sup>50,51</sup> The 3–4 and 3–3 crosslinked tripeptide-tetrapeptide dimeric PGNs are structural isomers that differ only in the isopeptide bond position, which were easily distinguished using our MS/MS-integrated PGN analysis workflow (Fig. 4C and S7†). Interestingly, across all bacteria, we also detected tetra-saccharide PGN dimers that are isomeric to the crosslinked dimers (Fig. S10†). Although such tetra-saccharide motifs are possible products of incomplete muramidase digestion during sample preparation, additional rounds of enzymatic digestion could not fully eliminate them.<sup>52</sup> Compared to the crosslinked PGN dimers, these tetra-saccharide PGNs generally yielded fewer MS/MS fragments with lower relative intensity for B-type fragments and higher intensity for L-type fragments (Fig. S10†), which is consistent with the presence of only one terminal GlcNAc and two free-stem peptides in these structures. The ability to easily identify such tetra-saccharide PGNs in our workflow may provide the impetus to investigate their physiological relevance in bacteria.

### Comprehensive and automated PGN profiling in gut bacteria

Encouraged by the proof-of-concept studies in model bacteria, we next set out to comprehensively profile the PGNs in a panel of human gut bacteria: *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium infantis*, *Fusobacterium nucleatum* and *Akkermansia muciniphila*. Among them, *A. muciniphila* and *Bifidobacterium* spp. are commensal species that help maintain the gut microbiota balance and reduce inflammation, whereas *F. nucleatum* is associated with colorectal and other cancers.<sup>21,22,53–55</sup> Notably, except for a recent study that analyzed PGNs in *A. muciniphila* using LC-MS,<sup>56</sup> our knowledge of *Bifidobacterium* and *F. nucleatum* PGNs is only from early studies in the 1970s.<sup>57–60</sup> To address their potential biological functions in the host, there is an imperative need to perform in-depth PGN profiling of these gut bacteria.

We first elucidated the canonical PGN makeup in the respective gut bacteria (Fig. 4B). *A. muciniphila* possesses mDAP-type PGNs,<sup>56</sup> similar to most other Gram-negative bacteria. However, *F. nucleatum* PGNs exclusively feature the non-proteinogenic lanthionine at the third position of the stem peptide, whose structure closely resembles that of mDAP.<sup>58,59</sup> On







Fig. 4 Summary of peptidoglycan compositions in the model (A) and gut bacteria (B) with the canonical makeup shown in bold and variable components not bolded. For instance, the canonical makeup in *E. coli* is (NAG)(NAM)-AemAA and the fifth amino acid, Ala, can be substituted with His, Gly, or Lys. The total number of PGNs identified in each species of bacteria is listed. Compositions for *E. faecalis* and *F. nucleatum* are shown in Fig. S8G† instead. PGN\_MS2 enables distinctions between isomeric PGNs by matching experimental spectra against *in silico* predicted MS/MS patterns for: (C) tetrapeptide-tripeptide dimers with either 3–4 or 3–3 crosslinks in *E. coli*; (D) monomeric PGNs that incorporate Gly at either the 4th or 5th position in *E. faecium*. The key fragments that are essential for resolving the respective isomers are highlighted in yellow. Fig. S6, S7, S9, and S10† showcase additional examples of differentiating isomeric PGNs by PGN\_MS2.

the other hand, Gram-positive *Bifidobacterium* spp. possess either L-Lys or L-Orn as the third residue that is further appended with distinct bridge peptides (Fig. 4B).<sup>57</sup> Surprisingly, we found that whereas the L-Lys containing PGNs are only minor

constituents in *B. bifidum* and *B. infantis* (2.7 and 3.6% respectively, Fig. S8B†), they are the major constituents in *B. adolescentis* (62.3%, Fig. S8B†). This could imply that MurE, the ligase that incorporates the third amino acid residue in soluble







**Fig. 5** Summary of peptidoglycan features in model and gut bacteria. (A) Varying lengths of stem peptide in monomeric PGNs across bacteria. (B) Amidation rate in stem peptides across bacteria. (C) Frequency of NCDAA incorporation in stem peptides across bacteria. (D) Amount of anNAM termini in bacteria. *Bifidobacterium* spp. show a high abundance of anNAM that differs from that of typical Gram-positive bacteria. All statistics indicate the relative muropeptide composition (in %) except for (B), where the amidation rate is instead defined as the number of amidated residues ( $\gamma$ -D-isoGln/ $\beta$ -D-isoAsn/mDAP(NH<sub>2</sub>)) per muropeptide. *L. plantarum*, *E. faecium*, and *B. adolescentis* feature two amidated amino acids, and the values shown are the combined rates for both. The data represent the average of three to four biological replicates with error bars representing standard deviations. Additional profiling analysis can be found in Fig. S8A–F.†

peptidoglycan precursors, exhibits unique substrate tolerances amongst different species of *Bifidobacterium*. Furthermore, *B. adolescentis* PGNs also sport an identical bridge peptide (*i.e.*,  $\beta$ -Asp/ $\beta$ -isoAsn) as those in *E. faecium* and *L. lactis*,<sup>42,61,62</sup> which are constructed by the sequential enzymatic activities of the D-aspartate ligase, Aslfm, and the asparagine synthase, AsnH.<sup>61–63</sup> Consistently, *B. adolescentis* encodes homologs of both enzymes (Table S14†).

Evaluating the lengths of stem peptides in PGNs across different bacteria, we found that PGNs in *F. nucleatum*, *B. infantis*, and *S. aureus* predominantly possess penta- and tetrapeptides, whereas *B. adolescentis*, *L. plantarum*, and *E. faecium* showcase variable PGNs with shorter stems ranging from one to four amino acids, which are likely products of enzymatic cleavages by DD-carboxypeptidases, LD-endopeptidases or DL-endopeptidases during PG maturation in bacteria (Fig. 5A).<sup>14</sup> Recent studies have revealed that SagaA-like DL-endopeptidases secreted by commensal gut bacteria such as *E. faecium* and *Lactobacillus* generate bioactive PGN motifs that regulate host gut homeostasis.<sup>42,64,65</sup> Interestingly, both *B. bifidum* and *B. adolescentis* have a significant proportion of PGNs with

dipeptide stems (~15%) (Fig. 5A), suggesting the activities of SagaA-like enzymes in these two *Bifidobacterium* that could be potentially relevant to their anti-inflammatory effects.

In all bacteria, NCDAA are commonly found in the stem peptides of PGNs, substituting D-Ala in the fourth or fifth position (Fig. 4A and B and 5B).<sup>12</sup> PGNs from *A. muciniphila* and *F. nucleatum* mostly contain basic NCDAA such as His, Arg, Asn, or Lys at the fifth position of the stem peptides (Fig. 4B and S8G†), which could be incorporated by transpeptidases and/or Ddl in these bacteria.<sup>66</sup> Notably, *E. coli* possesses the greatest diversity of NCDAA in PGNs, including Phe, Tyr, Gly, Lys, Cys, Arg, *etc.*, whereas other bacteria, *B. adolescentis*, *B. infantis*, *L. plantarum*, and *S. aureus* appear to solely utilize Gly as the non-canonical amino acid in the PGN stem peptides (Fig. 4A and B). Empowered by *in silico* MS/MS spectral references, we readily distinguished PGN isomers with Gly at either the fourth or fifth position of the pentapeptide stem in *E. faecium* (Fig. 4D). NCDAA in peptidoglycan confer bacterial resistance against hydrolases of rival bacterial species, which are consistently found at elevated levels in bacteria under stress conditions.<sup>12,67</sup> Our work reveals the widespread presence of NCDAA in





bacterial PGNs under steady-state conditions compared to what was previously appreciated.

Besides stem peptide motifs, we also profiled structural features on the (NAG)(NAM) backbone in PGNs across bacteria, including *O*-acetylation (*i.e.*, DAG and DAM) or de-*N*-acetylation (*i.e.*, G and MUR) (Fig. 4A and B).<sup>68</sup> Modifications to acetylation in peptidoglycan may help bacteria evade lytic enzymes such as lysozyme.<sup>69</sup> With our MS/MS-integrated analysis workflow, we could readily determine if acetylation/de-acetylation occurs on the NAG or NAM residue in disaccharide PGNs. Such alterations only account for a minor extent (<5%) in PGNs of *B. bifidum* and *L. plantarum*; hence no significant changes in the overall acetylation rate of PGNs were observed for most bacteria (Fig. S8E and F†). One remarkable exception is *A. muciniphila* that showcases 43% de-*N*-acetylation of NAG (Fig. S8E and F†), which is in good agreement with the recent analysis by Garcia-Vello *et al.* (~40%).<sup>56</sup> Notably, these de-*N*-acetylated PGNs are still potent agonists to both NOD1 and NOD2 immune sensors;<sup>56</sup> thus, it remains to be determined if such de-*N*-acetylated motifs exhibit any distinct functions in the host.

Next, 1,6-anhydroMurNAc (anNAM) termini are unique features that mark the end of the peptidoglycan strands in Gram-negative bacteria.<sup>20</sup> Correspondingly, anhydro-PGNs constituted 4–5% of total peptidoglycan composition in Gram-negative bacteria, *E. coli* and *F. nucleatum*, but are nearly undetectable in model Gram-positive bacteria and *A. muciniphila* (Fig. 5D).<sup>56</sup> Surprisingly, we found that all three *Bifidobacterium* spp. contain a remarkably high abundance of anhydro-PGNs, which is unusual for Gram-positive bacteria (Fig. 5D and S11†). For instance, the anNAM-containing PGNs comprise nearly 40% of total PGNs in *B. adolescentis* (Fig. 5D). The exceedingly high amounts of anhydro-PGNs in *Bifidobacterium* suggest the presence of active lytic transglycosylases (LTs) in catalyzing the non-hydrolytic cleavage of the peptidoglycan backbone, which are elusive in Gram-positive bacteria.<sup>52,70,71</sup> We next set out to establish putative LTs in *Bifidobacterium* responsible for anhydro-PGN formation.

### Identification and characterization of putative LTs in *Bifidobacterium*

To identify putative LTs in *Bifidobacterium*, we searched for homologous proteins containing the catalytic domains of known LTs in other species (*i.e.* *E. coli* MltA-G and Slt70).<sup>72</sup> Interestingly, all three *Bifidobacterium* species encode proteins (BaMltG, BbMltG and BiMltG) that possess the catalytic domain, IPR003770, of MltG, consistent with the broad conservation of MltG across bacteria (Fig. S12A and B†).<sup>73</sup> Protein sequence alignment with ClustalOmega revealed that BaMltG, BbMltG, and BiMltG are ~55–57% similar to one another and are 23–27% similar to *E. coli* MltG, *B. subtilis* MltG, and *S. pneumoniae* MpgA, whose biochemical activities have been characterized (Fig. S13A†).<sup>52,73,74</sup> While MltG in Gram-negative bacteria represents the sole inner membrane-bound LT that is responsible for the cleavage of nascent PG strands and generates 1,6-anhydro-MurNAc termini, the MltG homolog in *S. pneumoniae*, MpgA acts as a muramidase instead.<sup>52</sup>

Notably, the identity of a single amino acid in the active site of MltG serves as a key determinant for the corresponding enzymatic activity, with Asp for LTs and Asn for muramidases.<sup>52</sup> We found that *Bifidobacterium* MltG harbors an Asp at this position, implying its potential role as an LT (Fig. S13A†). For biochemical characterization of *Bifidobacterium* MltG, we cloned, over-expressed, and purified the respective MltG lacking the *N*-terminal transmembrane domain (Fig. 6B). Initial attempts at incubating the recombinant MltG protein with bacterial sacculi did not yield any products, which was in agreement with previous findings that mature sacculi are poor/not suitable substrates for MltG.<sup>52,73,74</sup> We next sought to evaluate the activity of *Bifidobacterium* MltG with nascent peptidoglycan as a substrate, generated from *in situ* Lipid II polymerization with SgtB.<sup>52,74</sup> Since it is challenging to isolate native Lipid II molecules from large-scale cultures of *Bifidobacterium*, it was substituted with *E. faecalis* Lipid II instead,<sup>75</sup> as its structure resembles that of *Bifidobacterium* Lipid II. We added *Bifidobacterium* MltG and SgtB to the Lipid II substrate, followed by mutanolysin to release soluble muropeptides for LC-MS analysis. As shown in Fig. 6A and B, the addition of *Bifidobacterium* MltG indeed led to a significant increase in anhydro-PGN products, indicating its robust LT activity *in vitro* (Fig. 6B and S14†). As a negative control, we showed that mutating the catalytic residue Asp to Ala in *Bifidobacterium* MltG completely abolishes the observed LT activity *in vitro* (Fig. S15†). In addition, we showed that Lipid II is not a substrate for *Bifidobacterium* MltG, as no LT products were detected in the absence of SgtB (Fig. S15†).

Apart from the well-characterized LTs in Gram-negative bacteria, certain Gram-positive bacteria that undergo dormancy also encode a large family of cell wall lytic enzymes that are known as resuscitation-promoting factors (Rpfs), some of which are LTs.<sup>76,77</sup> Since *Bifidobacterium* can also enter a viable but non-culturable (VBNC) state similar to dormancy,<sup>78,79</sup> we explored if *Bifidobacterium* could possess any Rpfs with LT activity. Using sequence similarity searching by BLAST, we identified two candidate proteins (RpfB-FL and RpfB-Truncated) in *Bifidobacterium* containing the lysozyme-like domain (IPR023346) that show weak homology to *M. tuberculosis* and *S. coelicolor* RpfB (Fig. S12A and C†). Interestingly, both the full-length and truncated RpfB proteins of *B. adolescentis* display dual LT and amidase activities with bacterial sacculi *in vitro* (Fig. S16†), indicating their possible involvement in sacculi remodeling. Taken together, our results established three *bona fide* LTs (MltG, RpfB-FL length, and RpfB-Truncated) in *Bifidobacterium* that may act in concert contributing to the high abundance of anNAM in *Bifidobacterium* peptidoglycan.

### *Bifidobacterium* anhydro-PGNs exhibit potent anti-inflammatory activity *in vitro*

Intrigued by the predominant anhydro-PGNs in *Bifidobacterium* spp., we hypothesize that the remarkable anti-inflammatory functions of *Bifidobacterium* spp. as probiotics may be attributed to these unique anhydro-PGN molecules. Although most bacterial PGNs belong to pathogen-associated molecular





Fig. 6 *Bifidobacterium* anhydro-PGNs from the cleavage of lytic transglycosylases (LTs) exhibit potent anti-inflammatory effects *in vitro*. (A) Biochemical reconstitution of recombinant *Bifidobacterium* MltG with nascent peptidoglycans as substrates. Lipid II was extracted from *E. faecalis*. (B) LC-MS chromatograms of the mucopeptide products indicate the formation of anhydro-PGNs, II. Extracted ion chromatograms (EICs) for the  $[M + 2H]^{2+}$  adduct are shown. Additional control experiments are shown in Fig. S15.† (C) Pre-treatment of synthetic anhydro-PGN (ah-PGN), (NAG)(NAM)-AeKAA, significantly suppresses LPS-induced inflammatory responses in murine macrophage RAW264.7 cells. The synthetic ah-PGN mimics the natural anhydro-PGNs found in *B. adolescentis*.

patterns (PAMPs) that are agonists of mammalian NOD immune sensors to trigger downstream proinflammatory responses,<sup>80</sup> these anhydro-PGN motifs in *Bifidobacterium* spp. lack critical structural features for both NOD1 and NOD2 activations. Specifically, *Bifidobacterium* PGNs harbor an L-Lys or L-Orn instead of mDAP in the stem peptide, rendering them non-agnostic to NOD1.<sup>81,82</sup> Moreover, these PGNs with 1,6-anhydro-MurNAc termini effectively evade NOD2 recognition, which strictly senses the reducing-end anomeric configuration of MurNAc in PGNs.<sup>83,84</sup> As expected, we demonstrated that crude PGNs of *B. adolescentis* exhibit significantly reduced capacity in activating NOD signaling pathways in cell-based reporter assays compared to PGNs of other Gram-positive and Gram-negative bacteria including *S. aureus*, *E. faecalis*, and *E. coli* (Fig. S17†), highlighting the distinct characteristics of PGNs from probiotic *Bifidobacterium* spp. To further explore the potential anti-inflammatory effects of these anhydro-PGNs, we used an *in vitro* immunological assay, where we pre-treated murine macrophage RAW264.7 cells with a synthetic anhydro-PGN before the addition of LPS, followed by gene expression analysis by RT-qPCR (Fig. 6C and S17†). To our surprise, the presence of the anhydro-PGN effectively suppressed the expressions of several key proinflammatory cytokines including *tnfa*, *il1b*, and *il6* in RAW264.7 induced by LPS, highlighting the potent anti-inflammatory properties of *Bifidobacterium* anhydro-PGNs *in vitro*.

## Discussion

With access to our open-access and customizable MS/MS-integrated PGN library, it is now possible to automate the

PGN analysis workflow. We demonstrated the use of an open-source program, MS-DIAL for data processing,<sup>34</sup> which easily performs the searching and scoring of the experimental data against our *in silico* PGN spectral reference, rendering the entire PGN identification process more accurate and robust than ever.

Firstly, our *in silico* PGN MS1 database, which centers around the (NAG)(NAM)-containing disaccharide mucopeptide as the core PGN structure, is customizable with user-defined parameters to accommodate diverse structural modifications and polymerizations/crosslinking in PGNs. Currently, our algorithms support most known PGN modifications as built-in selections, including *O*-acetylation, de-*N*-acetylation, NCDAA incorporation, 3–3/3–4 crosslinking, *etc.*; additional structural features can be conveniently incorporated to expand the search space for identification of novel PGNs in the gut microbiota.

Secondly, for each PGN molecule in the MS1 database, an *in silico* predicted MS/MS pattern is automatically generated by PGN\_MS2. The collection of these simulated MS/MS spectra affords a comprehensive *in silico* PGN spectral library that enables automated analysis. In contrast to PGFinder,<sup>35</sup> a PGN analysis pipeline based solely on MS1 values, our PGN MS library integrates *in silico* MS/MS spectral prediction, marking a significant advance for accurate and robust PGN identification. Similar to the iterative searching strategy in PGFinder,<sup>35</sup> we also recommend users specify selective parameters to build the *in silico* PGN polymer pool focusing on the major canonical features in the PGN monomers, to reduce the number of possible polymers created. As a novel feature of our PGN library, the PGN\_MS2 tool also outputs an image summarizing the diversity of PGNs with their respective nomenclatures and chemical- and PGN-specific properties.



Notably, our PGN\_MS2 represents a dedicated *in silico* MS/MS spectral prediction algorithm for PGNs, whose unique sugar and non-proteogenic amino acids defy reliable predictions by existing tools developed for small molecules or proteins. For instance, the proteomics analysis software Byonic has been previously used for PGN analysis,<sup>19</sup> which takes a peptide-centric approach such that common PGN structures are viewed as variable modifications of the stem peptide. As a result, one needs to manually annotate the masses of various moieties, such as anhydro- and de-acetylation of the disaccharide backbone, non-proteogenic and amidated amino acids for PGN search and analysis. In contrast, PGN\_MS2 is specialized to predict MS/MS spectra for PGN chemotypes, where the user simply selects the desired structural features of PGNs without needing to calculate and input their respective masses, rendering the analysis process user-friendly and flexible to accommodate novel modifications.

To validate the reliability of our workflow, we compared the cosine similarity scores between the *in silico* predicted spectra of PGNs and the authentic spectra of several PGN motifs. Remarkably, PGN\_MS2 consistently outperformed other spectral simulation software packages in metabolomics and proteomics. Moreover, the PGN\_MS2 predicted spectra matched well with the fragmentation data acquired using different instruments (*i.e.*, Orbitrap and Q-TOF), showcasing the congruity of the *in silico* PGN fragmentation rules. We further demonstrated the facile and accurate assignment of closely related PGN isomers *via* automated spectral matching and scoring. However, we also noted that the experimental MS/MS spectra of low abundant analytes tend to have lower quality, which led to the top predicted PGN structures having very close similarity scores. In these cases, manual inspections are needed to ensure accurate structural assignment. To facilitate such manual analysis, our PGN\_MS2 records the precursor, fragmentation type, and chemical structure of all fragment peaks generated (Fig. S2D†).

During the preparation of our manuscript, Hsu *et al.* reported a high-throughput automated mucopeptide analysis (HAMA) framework that generates *in silico* MS/MS fragments for PGN analysis.<sup>85</sup> However, we note several key distinctions between our workflow and HAMA. First, for *in silico* prediction of MS/MS patterns, HAMA focuses on fragmentation of the stem peptide, solely generating the b- and y-ions of stem peptides without any fragmentation of the sugar moieties in PGNs. Secondly, HAMA restricts the types of PGN modifications to <6 (including those on sugar motifs and peptide aminations *etc.*) to avoid mass coincidences. On the other hand, our PGN\_MS2 is developed especially for simulating MS/MS patterns of soluble mucopeptide chemotypes, whose fragmentation rules were derived from empirical analysis that include both sugar and peptide moieties in PGNs, showcasing superior matches to actual MS/MS data from HCD and CID fragmentations. As a result, our workflow accommodates much more diverse PGNs in the database and accurately distinguishes structural isomers by MS/MS matching. Notably, HAMA is reportedly unable to differentiate the 3–4 and 3–3 crosslinks in dimeric PGNs and hence can only consider 3–4 crosslinks currently. In contrast,

with our PGN workflow, the 3–4 and 3–3 crosslinked PGN isomers can be readily identified with signature fragments from the *in silico* MS/MS patterns (Fig. 4C and S7†). Moreover, our PGN\_MS2 also includes specific fragmentations pertinent to the isoGln/Glu (q1/q2 and e1/e2), exhibiting its unique power in determining the amidation positions on isomeric PGNs (Fig. S3 and S9†). Furthermore, PGN\_MS2 creates a PGN MS library that is compatible with various vendors or open-source MS analysis software, offering users flexibility in choosing their preferred platforms for data analysis. To promote open-access research in the PGN field, PGN\_MS2 itself is open source ([https://github.com/jerickwan/PGN\\_MS2](https://github.com/jerickwan/PGN_MS2)), where users can download directly to use or modify the code to increase the scope of fragmentations and the identities of amino acids and/or glycan motifs, *etc.* Recognizing the lack of PGNs in the existing metabolomics databank, we also uploaded the annotated MS/MS spectra of PGNs across different bacteria to the metabolomic data repository MoNA ([https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists\(tags.text:%27QiaoLab\\_PGN%27\)](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(tags.text:%27QiaoLab_PGN%27))).

Aided by PGN\_MS2, we uncovered that *Bifidobacterium* spp. features a large abundance of anNAM termini in peptidoglycan, which are non-hydrolytic cleavage products of LT enzymes.<sup>72</sup> By homology searching, we identified and biochemically characterized three enzymes as LTs in *Bifidobacterium*, namely, MltG, RpfB-FL, and RpfB-Truncated, respectively. Interestingly, MltG strictly requires nascent peptidoglycan strands as substrates for non-hydrolytic cleavage, whereas RpfBs robustly use mature sacculi to produce anhydro-NAM termini. The complementary substrate preferences of these LTs may account for the remarkably high amount of anhydro-PGNs. Importantly, *Bifidobacterium* spp. are well-known probiotics that confer beneficial effects on hosts such as reducing LPS-induced inflammation *in vitro* and *in vivo*.<sup>21,22</sup> We demonstrated that pretreatment with anhydro-PGN effectively suppressed LPS-induced proinflammatory cytokine expression in murine macrophages *in vitro*. As *Bifidobacterium* anhydro-PGNs are non-agnostic to canonical NOD1 and NOD2 immune receptors,<sup>81–84</sup> the underlying mechanisms of their anti-inflammatory roles are yet to be elucidated. We are currently working to genetically manipulate putative LTs in *Bifidobacterium* spp. to evaluate the anti-inflammatory activities of the mutants *in vivo*, which may lead to improved probiotics.

## Conclusions

In summary, we established a novel and robust PGN\_MS2 tool to facilitate automated PGN identification and analysis, addressing the key bottleneck in the current analysis workflow. Empowered by PGN\_MS2, we characterized the peptidoglycan composition of various gut bacteria species. We discovered an abundance of anhydro-PGNs (*i.e.*, LT products) in *Bifidobacterium* spp., which is unusual for Gram-positive bacteria, and further biochemically characterized three putative LTs in *Bifidobacterium*. Lastly, we established that *Bifidobacterium* anhydro-PGNs exhibit anti-inflammatory activity *in vitro*,





offering insights into novel bioactive PGNs in gut microbiota-host crosstalk.

## Data availability

PGN\_MS2 is available on GitHub ([https://github.com/jerickwan/PGN\\_MS2](https://github.com/jerickwan/PGN_MS2)). Annotated MS/MS spectra ofuropeptides have been deposited on MoNA ([https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists\(tags.text:%27QiaoLab\\_PGN%27\)](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(tags.text:%27QiaoLab_PGN%27))).

## Author contributions

J. M. C. K. and Y. Q. designed the research; J. M. C. K. performed coding and developed the PGN analysis pipeline; J. M. C. K. and E. W. L. N. performed biochemical characterization of Bifidobacterium LTs; Y. L. performed the *in vitro* assays with RAW264.7 and HEK-Blue reporter cells; Y. L., C. L., and Y. Z. contributed to LC-MS method development; E. K. and S. W. provided anaerobic cultures of the gut bacteria; X. Z. and X. L. provided synthetic ah-PGN for testing; J. M. C. K., Y. L. and Y. Q. analyzed the data; S. W. and Y. Q. supervised the work; J. M. C. K. and Y. Q. wrote the paper with inputs from all authors.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We acknowledge members of the Qiao lab for critical reading of the manuscript. J. M. C. K.'s PhD candidature is supported by the Nanyang Presidential Graduate Scholarship. This work was supported by the National Research Foundation (NRF) Singapore, NRF-NRFF12-2020-0006, NTU-Start-up grant, and MOE AcRF Tier 1, RG3/22 to Y. Q.

## Notes and references

- W. Vollmer, D. Blanot and M. A. De Pedro, *FEMS Microbiol. Rev.*, 2008, **32**, 149–167.
- O. Irazoki, S. B. Hernandez and F. Cava, *Front. Microbiol.*, 2019, **10**, 500.
- J. Dworkin, *Annu. Rev. Microbiol.*, 2014, **68**, 137–154.
- R. Wheeler, G. Chevalier, G. Eberl and I. Gomperts Boneca, *Cell. Microbiol.*, 2014, **16**, 1014–1023.
- J. D. Laman, B. A. 't Hart, C. Power and R. Dziarski, *Trends Mol. Med.*, 2020, **26**, 670–682.
- R. Wheeler, P. A. D. Bastos, O. Disson, A. Rifflet, I. Gabanyi, J. Spielbauer, M. Bérard, M. Lecuit and I. G. Boneca, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2209936120.
- M. E. Griffin, J. Espinosa, J. L. Becker, J. D. Luo, T. S. Carroll, J. K. Jha, G. R. Fanger and H. C. Hang, *Science*, 2021, **373**, 1040–1046.
- Z. Huang, J. Wang, X. Xu, H. Wang, Y. Qiao, W. C. Chu, S. Xu, L. Chai, F. Cottier, N. Pavelka, M. Oosting, L. A. B. Joosten, M. Netea, C. Y. L. Ng, K. P. Leong, P. Kundu, K. P. Lam, S. Pettersson and Y. Wang, *Nat. Microbiol.*, 2019, **4**, 766–773.
- T. Arentsen, Y. Qian, S. Gkatzis, T. Femenia, T. Wang, K. Udekwu, H. Forssberg and R. Diaz Heijtz, *Mol. Psychiatry*, 2017, **22**, 257–266.
- I. Gabanyi, G. Lepousez, R. Wheeler, A. Vieites-Prado, A. Nissant, S. Wagner, C. Moigneu, S. Dulauroy, S. Hicham, B. Polomack, F. Verny, P. Rosenstiel, N. Renier, I. G. Boneca, G. Eberl and P.-M. Lledo, *Science*, 2022, **376**, eabj3986.
- K. L. Bersch, K. E. DeMeester, R. Zagani, S. Chen, K. A. Wodzanowski, S. Liu, S. Mashayekh, H.-C. Reinecker and C. L. Grimes, *ACS Cent. Sci.*, 2021, **7**, 688–696.
- P. Horcajo, M. A. de Pedro and F. Cava, *Microb. Drug Resist.*, 2012, **18**, 306–313.
- A. J. F. Egan, J. Errington and W. Vollmer, *Nat. Rev. Microbiol.*, 2020, **18**, 446–460.
- J. M. C. Kwan and Y. Qiao, *ChemBioChem*, 2023, **24**, e202200693.
- B. Glauner, *Anal. Biochem.*, 1988, **172**, 451–464.
- D. Kühner, M. Stahl, D. D. Demircioglu and U. Bertsche, *Sci. Rep.*, 2014, **4**, 1–7.
- E. M. Anderson, D. Sychantha, D. Brewer, A. J. Clarke, J. Geddes-McAlister and C. M. Khursigara, *J. Biol. Chem.*, 2020, **295**, 504–516.
- E. M. Anderson, N. Shaji Saji, A. C. Anderson, D. Brewer, A. J. Clarke and C. M. Khursigara, *mSystems*, 2022, **7**(3), e00156.
- M. Bern, R. Beniston and S. Mesnage, *Anal. Bioanal. Chem.*, 2017, **409**, 551–560.
- S. Porfirio, R. W. Carlson and P. Azadi, *Trends Microbiol.*, 2019, **27**, 607–622.
- S. Singh, R. Bhatia, P. Khare, S. Sharma, S. Rajarammohan, M. Bishnoi, S. K. Bhadada, S. S. Sharma, J. Kaur and K. K. Kondepudi, *Sci. Rep.*, 2020, **10**, 18597.
- S. Sun, L. Luo, W. Liang, Q. Yin, J. Guo, A. M. Rush, Z. Lv, Q. Liang, M. A. Fischbach, J. L. Sonnenburg, D. Dodd, M. M. Davis and F. Wang, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 27509–27515.
- G. Landrum, *RDKit: Open-source cheminformatics*, <https://www.rdkit.org>, accessed 20 May 2022.
- C. Ruttkies, E. L. Schymanski, S. Wolf, J. Hollender and S. Neumann, *J. Cheminf.*, 2016, **8**, 1–16.
- T. Kind, K.-H. H. Liu, D. Y. Lee, B. Defelice, J. K. Meissen and O. Fiehn, *Nat. Methods*, 2013, **10**, 755–758.
- F. Wang, J. Liigand, S. Tian, D. Arndt, R. Greiner and D. S. Wishart, *Anal. Chem.*, 2021, **93**, 11692–11700.
- S. Degroevé, D. Maddelein and L. Martens, *Nucleic Acids Res.*, 2015, **43**, W326–W330.
- T. Kind, H. Tsugawa, T. Cajka, Y. Ma, Z. Lai, S. S. Mehta, G. Wohlgemuth, D. K. Barupal, M. R. Showalter, M. Arita and O. Fiehn, *Mass Spectrom. Rev.*, 2018, **37**, 513–532.
- C. T. Tan, X. Xu, Y. Qiao and Y. Wang, *Nat. Commun.*, 2021, **12**, 2560.
- B. Domon and C. E. Costello, *Glycoconjugate J.*, 1988, **5**, 397–409.





- 31 P. Zhang, W. Chan, I. L. Ang, R. Wei, M. M. T. Lam, K. M. K. Lei and T. C. W. Poon, *Sci. Rep.*, 2019, **9**, 6453.
- 32 S. E. Stein and D. R. Scott, *J. Am. Soc. Mass Spectrom.*, 1994, **5**, 859–866.
- 33 D. Szabó, G. Schlosser, K. Vékey, L. Drahos and Á. Révész, *J. Mass Spectrom.*, 2021, **56**, e4693.
- 34 H. Tsugawa, K. Ikeda, M. Takahashi, A. Satoh, Y. Mori, H. Uchino, N. Okahashi, Y. Yamada, I. Tada, P. Bonini, Y. Higashi, Y. Okazaki, Z. Zhou, Z. J. Zhu, J. Koelmel, T. Cajka, O. Fiehn, K. Saito, M. Arita and M. Arita, *Nat. Biotechnol.*, 2020, **38**, 1159–1163.
- 35 A. V. Patel, R. D. Turner, A. Rifflet, A. E. Acosta-Martin, A. Nichols, M. M. Awad, D. Lyras, I. G. Boneca, M. Bern, M. O. Collins and S. Mesnage, *eLife*, 2021, **10**, 1–4.
- 36 B. Glauner, J. V. Holtje and U. Schwarz, *J. Biol. Chem.*, 1988, **263**, 10088–10095.
- 37 B. L. M. De Jonge, Y. S. Chang, D. Gage and A. Tomasz, *J. Biol. Chem.*, 1992, **267**, 11248–11254.
- 38 S. Willing, E. Dyer, O. Schneewind and D. Missiakas, *J. Biol. Chem.*, 2020, **295**, 13664–13676.
- 39 J. D. Chang, A. G. Wallace, E. E. Foster and S. J. Kim, *Biochemistry*, 2018, **57**, 1274–1283.
- 40 S. Magnet, A. Arbeloa, J. L. Mainardi, J. E. Hugonnet, M. Fourgeaud, L. Dubost, A. Marie, V. Delfosse, C. Mayer, L. B. Rice and M. Arthur, *J. Biol. Chem.*, 2007, **282**, 13151–13159.
- 41 J. D. Chang, E. E. Foster, A. G. Wallace and S. J. Kim, *Sci. Rep.*, 2017, **7**, 1–8.
- 42 B. Kim, Y.-C. Wang, C. W. Hespden, J. Espinosa, J. Salje, K. J. Rangan, D. A. Oren, J. Y. Kang, V. A. Pedicord and H. C. Hang, *eLife*, 2019, **8**, e45343.
- 43 E. Bernard, T. Rolain, P. Courtin, A. Guillot, P. Langella, P. Hols and M.-P. Chapot-Chartier, *J. Biol. Chem.*, 2011, **286**, 23950–23958.
- 44 A. J. Apostolos, S. E. Pidgeon and M. M. Pires, *ACS Chem. Biol.*, 2020, **15**, 1261–1267.
- 45 F. Ngadjoua, E. Braud, S. Saidjalolov, L. Iannazzo, D. Schnappinger, S. Ehrhart, J. E. Hugonnet, D. Mengin-Lecreulx, D. Patin, M. Ethève-Quellejeu, M. Fonvielle and M. Arthur, *Chem.–Eur. J.*, 2018, **24**, 5743–5747.
- 46 A. Zapun, J. Philippe, K. A. Abrahams, L. Signor, D. I. Roper, E. Breukink and T. Vernet, *ACS Chem. Biol.*, 2013, **8**, 2688–2696.
- 47 S. E. Pidgeon, A. J. Apostolos, J. M. Nelson, M. Shaku, B. Rimal, M. N. Islam, D. C. Crick, S. J. Kim, M. S. Pavelka, B. D. Kana and M. M. Pires, *ACS Chem. Biol.*, 2019, **14**, 2185–2196.
- 48 A. J. Apostolos, J. M. Nelson, J. R. A. Silva, J. Lameira, A. M. Achimovich, A. Gahlmann, C. N. Alves and M. M. Pires, *ACS Chem. Biol.*, 2020, **15**, 2966–2975.
- 49 A. M. Strandén, M. Roos and B. Berger-Bächi, *Microb. Drug Resist.*, 1996, **2**, 201–207.
- 50 J.-E. Hugonnet, D. Mengin-Lecreulx, A. Monton, T. den Blaauwen, E. Carbonnelle, C. Veckerlé, Y. V. Brun, M. van Nieuwenhze, C. Bouchier, K. Tu, L. B. Rice and M. Arthur, *eLife*, 2016, **5**, e19469.
- 51 N. Morè, A. M. Martorana, J. Biboy, C. Otten, M. Winkle, C. K. G. Serrano, A. Montón Silva, L. Atkinson, H. Yau, E. Breukink, T. den Blaauwen, W. Vollmer and A. Polissi, *mBio*, 2019, **10**(1), e02729.
- 52 A. Taguchi, J. E. Page, H.-C. T. Tsui, M. E. Winkler and S. Walker, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2103740118.
- 53 S. H. Wong and J. Yu, *Nat. Rev. Gastroenterol. Hepatol.*, 2019, **16**(11), 690–704.
- 54 P. D. Cani and W. M. de Vos, *Front. Microbiol.*, 2017, **8**, 1–8.
- 55 J. Chen, X. Chen and C. L. Ho, *Front. Bioeng. Biotechnol.*, 2021, **9**, 770248.
- 56 P. Garcia-Vello, H. L. P. Tytgat, J. Gray, J. Elzinga, F. Di Lorenzo, J. Biboy, D. Vollmer, C. De Castro, W. Vollmer, W. M. de Vos and A. Molinaro, *Glycobiology*, 2022, 1–8.
- 57 O. Kandler, *Int. J. Syst. Bacteriol.*, 1970, **20**, 491–507.
- 58 E. N. Vasstrand, T. Hofstad, C. Endresen and H. B. Jensen, *Infect. Immun.*, 1979, **25**, 775–780.
- 59 K. Kato, T. Umemoto, H. Sagawa and S. Kotani, *Curr. Microbiol.*, 1979, **3**, 147–151.
- 60 E. N. Vasstrand, *Infect. Immun.*, 1981, **33**, 75–82.
- 61 S. Bellais, M. Arthur, L. Dubost, J.-E. Hugonnet, L. Gutmann, J. van Heijenoort, R. Legrand, J.-P. Brouard, L. Rice and J.-L. Mainardi, *J. Biol. Chem.*, 2006, **281**, 11586–11594.
- 62 P. Veiga, S. Piquet, A. Maisons, S. Furlan, P. Courtin, M. P. Chapot-Chartier and S. Kulakauskas, *Mol. Microbiol.*, 2006, **62**, 1713–1724.
- 63 P. Veiga, M. Erkelenz, E. Bernard, P. Courtin, S. Kulakauskas and M. P. Chapot-Chartier, *J. Bacteriol.*, 2009, **191**, 3752–3757.
- 64 J. Gao, X. Zhao, S. Hu, Z. Huang, M. Hu, S. Jin, B. Lu, K. Sun, Z. Wang, J. Fu, R. K. Weersma, X. He and H. Zhou, *Cell Host Microbe*, 2022, **30**, 1435–1449.e9.
- 65 J. Gao, L. Wang, J. Jiang, Q. Xu, N. Zeng, B. Lu, P. Yuan, K. Sun, H. Zhou and X. He, *Nat. Commun.*, 2023, **14**, 3338.
- 66 F. Cava, M. A. De Pedro, H. Lam, B. M. Davis and M. K. Waldor, *EMBO J.*, 2011, **30**, 3442–3453.
- 67 N.-H. Le, K. Peters, A. Espaillet, J. R. Sheldon, J. Gray, G. Di Venanzio, J. Lopez, B. Djahanschiri, E. A. Mueller, S. W. Hennon, P. A. Levin, I. Ebersberger, E. P. Skaar, F. Cava, W. Vollmer and M. F. Feldman, *Sci. Adv.*, 2020, **6**, eabb5614.
- 68 W. Vollmer, *FEMS Microbiol. Rev.*, 2008, **32**, 287–306.
- 69 K. M. Davis and J. N. Weiser, *Infect. Immun.*, 2011, **79**, 562–570.
- 70 H. C. T. Tsui, J. J. Zheng, A. N. Magallon, J. D. Ryan, R. Yunck, B. E. Rued, T. G. Bernhardt and M. E. Winkler, *Mol. Microbiol.*, 2016, **100**, 1039–1065.
- 71 M. R. Stapleton, M. J. Horsburgh, E. J. Hayhurst, L. Wright, I. M. Jonsson, A. Tarkowski, J. F. Kokai-Kun, J. J. Mond and S. J. Foster, *J. Bacteriol.*, 2007, **189**, 7316–7325.
- 72 D. A. Dik, D. R. Marous, J. F. Fisher and S. Mobashery, *Crit. Rev. Biochem. Mol. Biol.*, 2017, **52**, 503–542.
- 73 R. Yunck, H. Cho and T. G. Bernhardt, *Mol. Microbiol.*, 2016, **99**, 700–718.
- 74 J. Sassine, M. Pazos, E. Breukink and W. Vollmer, *Cell Surf.*, 2021, **7**, 100053.



- 75 M. A. Welsh, A. Taguchi, K. Schaefer, D. Van Tyne, F. Lebreton, M. S. Gilmore, D. Kahne and S. Walker, *J. Am. Chem. Soc.*, 2017, **139**, 17727.
- 76 V. D. Nikitushkin, G. R. Demina, M. O. Shleeva, S. V. Guryanova, A. Ruggiero, R. Berisio and A. S. Kaprelyants, *FEBS J.*, 2015, **282**, 2500–2511.
- 77 D. L. Sexton, R. J. St-Onge, H. J. Haiser, M. R. Yousef, L. Brady, C. Gao, J. Leonard and M. A. Elliot, *J. Bacteriol.*, 2015, **197**, 848–860.
- 78 S. J. Lahtinen, M. Gueimonde, A. C. Ouwehand, J. P. Reinikainen and S. J. Salminen, *Appl. Environ. Microbiol.*, 2005, **71**, 1662–1663.
- 79 A. R. Ortiz Camargo, O. van Mastrigt, R. S. Bongers, K. Ben-Amor, J. Knol, T. Abee and E. J. Smid, *Microbiol. Spectr.*, 2023, **11**, e0256822.
- 80 A. J. Wolf and D. M. Underhill, *Nat. Rev. Immunol.*, 2017, **18**(4), 243–254.
- 81 S. E. Girardin, I. G. Boneca, L. A. M. Carneiro, A. Antignac, M. Jéhanno, J. Viala, K. Tedin, M. K. Taha, A. Labigne, U. Zähringer, A. J. Coyle, P. S. DiStefano, J. Bertin, P. J. Sansonetti and D. J. Philpott, *Science*, 2003, **300**, 1584–1587.
- 82 Y. Fujimoto, A. R. Pradipta, N. Inohara and K. Fukase, *Nat. Prod. Rep.*, 2012, **29**, 568–579.
- 83 S. E. Girardin, I. G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D. J. Philpott and P. J. Sansonetti, *J. Biol. Chem.*, 2003, **278**, 8869–8872.
- 84 N. Inohara, Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, S. J. Foster, A. P. Moran, J. L. Fernandez-Luna and G. Nuñez, *J. Biol. Chem.*, 2003, **278**, 5509–5512.
- 85 H. Ya-Chen, S. Pin-Rui, H. Lin-Jie, C. Kum-Yi, C. Chun-hsien and H. Cheng-Chih, *eLife*, 2023, **12**, 88491.

